Staphylococcus infection is caused by different types of Staphylococcus bacteria which is basically a gram-positive bacteria that can cause a wide range of infections in human body such as skin infection, food poisoning, toxic shock syndrome and other. Staphylococcal bacteria are typically found on the skin and in the nostrils of humans. Transmission to human via contaminated hands, contact with infected or colonized site or fomites; airborne droplet spread is rare. Staphylococcus aureus is the primary causing agent for a number of different skin diseases. Staphylococcus infection is traditionally treated with antibiotics but in severe cases, there are different methods of treatment. The most common staphylococcal infections include impetigo, boils, carbuncles, abscesses, and infected wounds. Methicillin-resistant Staphylococcus aureus (MRSA) is the most common cause of community-acquired bacterial skin infections in the U.S.
Staphylococcal Infection Treatment Market: Drivers and Restraint
Key driving factors which is fueling the growth of Staphylococcal infection treatment market are increasing prevalence of the infectious disease such as skin infections, pneumonia, etc. and rising awareness of these disease among the general population. In addition, Improved screening of antibiotic-resistant strains of bacteria by utilizing advanced diagnostic tools, and an upsurge in the utilization of antibiotics worldwide are also considered as one of the key factors which is expected to fuel the growth of the global Staphylococcal infection treatment market. However, the difficulty to diagnose patients based on clinical presentation, dearth of skilled professional and poor healthcare infrastructure in emerging economies may hamper the Staphylococcal infection treatment market growth during the forecast period.
Download sample copy of this report:
Staphylococcal Infection Treatment Market: Segmentation
The global market for Staphylococcal infection treatment segmented by drug class, indication, route of administration, distribution channel, and geography:
- Based on Drug Class, Staphylococcal Infection Treatment is segmented into following: Lipopeptide Oxazolidinone Methicillin Penicillin Others
- Based on Route of Administration, Staphylococcal Infection Treatment is segmented into following: Oral Parenteral
- Based on Indication, Staphylococcal Infection Treatment is segmented into following: Skin infection Skin Abscess Impetigo Cellulitis Folliculitis Others Pneumonia Food poisoning Toxic shock syndrome Blood poisoning (bacteremia)
- Based on Distribution Channel, Staphylococcal Infection Treatment is segmented into following: Hospitals Retail Pharmacies e-Commerce/Online Pharmacies
- Based on Geography, Staphylococcal Infection Treatment is segmented into following: North America Latin America Western Europe Eastern Europe Asia Pacific excluding Japan and China Japan China Middle East and Africa
Staphylococcal Infection Treatment Market: Overview
Infectious disease are the second major cause of death worldwide. Intensive research is being carried out in order to develop novel drug classes which means that the effectiveness of the existing drugs in treating all strains of the Staphylococcal Infection is insufficient. Presently all major anti-infective lacks innovation and efficacy.
Due to the high range of generic antibiotics products used in the treatment of staphylococcal infections, there is a need for development of vaccines According to SENTRY Antimicrobial Surveillance Program, Widespread antibiotic use, the presence of intravascular catheter, severe underlying disease, prolonged hospitalization, and poor adherence to infection control precautions have contributed to the rise in MRSA rates. Western Pacific region 46%, Latin America 35%, United States 34%, Europe 26%, and Canada 6%. However, partnerships and collaborations amongst major companies have played a vital role in the enhancement of the Staphylococcal infection treatment market.
Staphylococcal Infection Treatment Market: Region-wise Outlook
Based on geographic region Staphylococcal infection treatment are classified into five key regions, North, America, Latin America, Europe, Asia-Pacific, Japan, Middle East and Africa. The market in North America is supposed to hold the largest revenue share of Staphylococcal infection treatment in the global market, followed by Europe, government initiative and established healthcare system is attributed to boosting the market growth. However, growing awareness about the antibiotic-resistant bacterial infections in the emerging economies of Asian countries, and rising incidence of skin infection in India & China are the major factors for the growth of Asia Pacific Staphylococcal infection treatment. Furthermore, increasing diagnosis rate and high adoption of treatment for skin in infection conditions are expected to prove favorable for the growth of the Staphylococcal infection treatment market
Buy Now to Get 10% Off and Free Customization as per Requirement:
Staphylococcal Infection Treatment Market: Key Market Participants
The key market players in the global Staphylococcal infection treatment market are Basilea Pharmaceutica Ltd., The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc., Allergan, Merck & Co., Inc., and other. The key player indulges in strategic initiatives like collaboration, acquisition and merger and product launch in the recent years. Pharmaceutical companies are focusing on developing distribution channels in untapped markets, increasing their sales force in untapped markets, and entering into strategic partnerships with local distributors.